Proximity Capital
Milan, Italy3
6M
2
0.38
0.33
- Areas of investment
Investor highlights
- Industry generalist
- Yes
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Rounds per year
- 0.38
- Follow on index
- 0.33
- Investments by industry
- Software (2)
- Crowdsourcing (2)
- InsurTech (2)
- Mobile (2)
- Insurance (2) Show 2 more
- Investments by region
- Italy (3)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 5
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Insoore | 07 Apr 2022 | Software, Mobile, Insurance, InsurTech, Crowdsourcing, Risk Management | Early Stage Venture | 6M | Lazio, Rome, Italy |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Parabilis Medicines , a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer | Aug 1, 2026 | Biopharmaceutical, Cancer Treatment | - | 305000000 USD | MA-based clinical-stage biopharmaceutical company, a Cambridge |
| Tubulis | Oct 15, 2025 | ADC platform technologies, Antibody-drug conjugates, Antibody Drug Conjugates, Biotechnology, Clinical Trials, Oncology | - | 361000000 USD |  Munich, Bavaria |
| AIRNA | Jan 4, 2025 | Biotech, Cardiometabolic diseases, RNA editing therapeutics | - | 155000000 USD |  Cambridge, Massachusetts |
| MeWe | Sep 10, 2024 | AI, Algorithmic Manipulation Avoidance, Blockchain, Cloud Storage, Privacy, Social Media, Social Network, Web3 | Early Growth stage | 6000000 USD | Los Angeles, California |
| FogPharma | Mar 3, 2024 | Biopharmaceutical, Cancer Therapeutics, Helicon Polypeptides, Helicon™ therapeutics, Intracellular drug targets | Late stage | 145000000 USD | Cambridge, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.